12,372 trials
Head and Neck Cancer · Mucositis Oral · Radiation Toxicity
Primary: Comparison of Number of Participants With Grade 1 or 2 Oral Mucositis (GM-CSF and SS Groups Only) — 28; 46 participants — p=0.09
Multiple Myeloma
Primary: Number of Participants With Response to Treatment at Day 1 of Cycle 5 — 1; 2; 2; 1 Participants
Prostatic Neoplasms
Primary: Overall Survival — 450.0; 332.0 Days — p=<0.0001
Gastric Cancer
Primary: Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments — 4.4; 5.6 months — p=0.3158
Cardiac Catheterization · Spasm
Primary: Change in Radial Artery Diameter — -5.6; 16.5 Percent change
Intestinal Behçet's Disease
Primary: Number of Participants With Marked Improvement at Week 24 — 9 participants
Heart Disease · Stroke · Ischemic Heart Disease
Primary: Event Rate Per 100 Patient Years for Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death — 7.93; 7.47 events per 100 patient-years — p=0.40
Cataract
Primary: Proportion of Subjects With Clinical Cure at Day 14 — 80.3; 39.3 Percentage of subjects — p=<0.0001
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean IOP at Month 3 for Each Assessment Timepoint (8 AM, + 2 h, + 7 h, and + 9 h) — 20.5; 21.6; 23.3; 17.2 millimeters mercury (mm Hg)
Pain · Cancer
Primary: Percentage of Participants Achieving Pain Control — 81.8 Percentage of Participants
Heart Failure · Myocardial Ischemia
Primary: Change in Physical Capacity Measured Using the 6-minute Walk Test Distance — 24.5; 21.3 meters
Knee Arthritis
Primary: Alignment of Knee - Measured Mechanical Axis From CT Data — -1.7; -1.3 degrees
Autism · Attention Deficit Disorder With Hyperactivity
Primary: Mean Conners' Teacher ADHD Index T Score by Dose — 72.8; 63.1; 63.6; 61.5 Units on a scale (T-scores) — p==.001
Migraine Disorders
Primary: Pain Free at Two Hours — 40; 21 participants
Pain, Postoperative
Primary: Summed, Time-weighted Pain Intensity Difference From 0 to 24 Hours Postdose (SPID0-24) — 23.2; 23.6; -0.6 Score on the scale